Diabetic Nephropathy Type 2 Clinical Trials

5 recruiting

Diabetic Nephropathy Type 2 Trials at a Glance

6 actively recruiting trials for diabetic nephropathy type 2 are listed on ClinicalTrialsFinder across 6 cities in 4 countries. The largest study group is Not Applicable with 1 trial, with the heaviest enrollment activity in Beijing, Changsha, and Hangzhou. Lead sponsors running diabetic nephropathy type 2 studies include Chinese PLA General Hospital, Medical College of Wisconsin, and Optithera.

Browse diabetic nephropathy type 2 trials by phase

Treatments under study

About Diabetic Nephropathy Type 2 Clinical Trials

Looking for clinical trials for Diabetic Nephropathy Type 2? There are currently 5 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Diabetic Nephropathy Type 2 trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Diabetic Nephropathy Type 2 clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 16 of 6 trials

Recruiting

Mixed Methods Study of Health-Related Social Needs in African American Adults With Chronic Kidney Disease and Type 2 Diabetes Mellitus

Chronic Kidney DiseasesDiabetes Mellitus, Type 2Diabetic Nephropathy Type 2 - Uncontrolled
Medical College of Wisconsin330 enrolled1 locationNCT05692388
Recruiting
Phase 1Phase 2

Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cell Therapy in Diabetic Nephropathy Patients: A Clinical Trial

Diabetic Nephropathy Type 2
PT. Prodia Stem Cell Indonesia10 enrolled1 locationNCT07396155
Recruiting

Research on Gut Microbiota and Metabolomics in Diabetic Kidney Disease

Type 2 Diabetes Mellitus (T2DM)Chronic Kidney DiseaseDiabetic Nephropathy Type 2
The First Affiliated Hospital of Hunan University of Traditional Chinese Medicine720 enrolled1 locationNCT06833541
Recruiting
Not Applicable

Clinical Utility of a Genomic Predictor Test on the Management of Cardiorenal Complications of Type 2 Diabetes

Cardiovascular DiseasesDiabetes Mellitus, Type 2Diabetic Nephropathy Type 2
Optithera2,714 enrolled2 locationsNCT06586203
Recruiting

Multidimensional Accurate Diagnosis and Treatment Technology and Clinical Transformation of Type 2 Diabetes Nephropathy

Type 2 DiabetesDiabetic Kidney DiseaseDiabetic Nephropathy Type 2
Chinese PLA General Hospital2,000 enrolled1 locationNCT05888909
Recruiting

Screening and Application Research of Early Diabetic Nephropathy Markers Based on Lipidomics.

BiomarkerDiabetic Nephropathy Type 2
Second Affiliated Hospital, School of Medicine, Zhejiang University1,000 enrolled1 locationNCT04931537